Nasopharyngeal carcinoma
Showing 1 - 25 of 8,214
Nasopharyngeal Carcinoma Trial in Wuhan (KSD-101)
Not yet recruiting
- Nasopharyngeal Carcinoma
- KSD-101
-
Wuhan, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
Oct 19, 2023
Nasopharyngeal Carcinoma Trial in Hangzhou (Endostar and Envafolimab)
Recruiting
- Nasopharyngeal Carcinoma
- Endostar and Envafolimab
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 24, 2023
Nasopharyngeal Carcinoma by AJCC V8 Stage Trial (New-mode reduce-volume target IMRT)
Not yet recruiting
- Nasopharyngeal Carcinoma by AJCC V8 Stage
- New-mode reduce-volume target IMRT
- (no location specified)
Oct 18, 2023
Nasopharyngeal Carcinoma Screening Based on Tongue Imaging
Not yet recruiting
- Nasopharyngeal Carcinoma
- Tongue image
-
Zhuhai, ChinaThe Fifth Affiliated Hospital of Sun Yat sen University
Nov 10, 2023
Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity
Not yet recruiting
- Nasopharyngeal Carcinoma
-
Fuzhou, Fujian, ChinaDepartment of radiation oncology, Fujian cancer hospital
Nov 16, 2023
Nasopharyngeal Carcinoma Trial in Hangzhou (Toripalimab)
Recruiting
- Nasopharyngeal Carcinoma
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Apr 2, 2023
Spatial Transcriptomics of Stage IVa Nasopharyngeal Carcinoma
Not yet recruiting
- Stage IVA Nasopharyngeal Carcinoma
- Intensity modulated radiation therapy (IMRT) combined with chemotherapy
-
Nanjing, ChinaJiangsu Cancer Hospital
Jun 21, 2023
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors Trial (Cadonilimab, Gemcitabine, Cisplatin)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Immune Checkpoint Inhibitors
- Cadonilimab
- +2 more
- (no location specified)
Jun 1, 2023
Nasopharyngeal Carcinoma, Iron-deficiency, Anemia Trial in Guangzhou (Iron Isomaltoside 1000, Polysaccharide Iron Complex Pill,
Recruiting
- Nasopharyngeal Carcinoma
- +2 more
- Iron Isomaltoside 1000
- +2 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Jun 19, 2023
Nasopharyngeal Carcinoma Trial in Zhongshan (participants will undergo dual-energy CT and endoscopy)
Recruiting
- Nasopharyngeal Carcinoma
- participants will undergo dual-energy CT and endoscopy
-
Zhongshan, Guangdong, ChinaZhongshan People's Hospital
May 22, 2023
Nasopharyngeal Carcinoma Trial in Zhongshan (Anrotinib plus Tirelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Anrotinib plus Tirelizumab
-
Zhongshan, Guangdong, ChinaZhongshan City People's Hospital
Jul 31, 2023
Predict Severe Oral Mucositis Associated With Chemoradiotherapy
Not yet recruiting
- Nasopharyngeal Carcinoma
- Oral Mucositis
- observational group
- (no location specified)
Sep 11, 2023
Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy Trial in Zhongshan (Reduction CTVp1, Non-reduction CTVp1)
Recruiting
- Nasopharyngeal Carcinoma
- Intensity-Modulated Radiotherapy
- Reduction CTVp1
- Non-reduction CTVp1
-
Zhongshan, Guangdong, ChinaZhongshan City People's Hospital
Aug 8, 2023
Nasopharyngeal Carcinoma Trial in Wuhan (Cadonilimab)
Recruiting
- Nasopharyngeal Carcinoma
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Mar 27, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma
- Camrelizumab
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023
Acute Radiation Induced Oral Mucositis in Nasopharyngeal
Recruiting
- Nasopharyngeal Carcinoma by AJCC V8 Stage
- Routine oral care
-
Guangzhou, Guangdong, ChinaYu Zeng
May 16, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (mobile platform or not mobile platform)
Recruiting
- Nasopharyngeal Carcinoma
- mobile platform or not mobile platform
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Apr 17, 2023
Nasopharyngeal Carcinoma Trial in Singapore (CCRT with Maintenance Tislelizumab and Metronomic Capecitabine)
Not yet recruiting
- Nasopharyngeal Carcinoma
- CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
-
Singapore, Singapore
- +1 more
Oct 16, 2023
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 Trial
Not yet recruiting
- Metastatic Nasopharyngeal Carcinoma
- +2 more
- Nivolumab
- +5 more
- (no location specified)
Aug 21, 2023
Nasopharyngeal Carcinoma Trial in Fuzhou (without concurrent cisplatin chemo, with concurrent cisplatin chemo)
Not yet recruiting
- Nasopharyngeal Carcinoma
- without concurrent cisplatin chemotherapy
- with concurrent cisplatin chemotherapy
-
Fuzhou, Fujian, ChinaDepartment of radiation oncology, Fujian cancer hospital
Oct 18, 2023
Nasopharyngeal Carcinoma Trial (Envafolimab and recombinant human endostatin combined with chemoradiotherapy)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Envafolimab and recombinant human endostatin combined with chemoradiotherapy
- (no location specified)
Sep 23, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou, Zhongshan, Nanning (IMRT and concurrent cisplatin, gemcitabine and cisplatin
Not yet recruiting
- Nasopharyngeal Carcinoma
- IMRT and concurrent cisplatin
- gemcitabine and cisplatin (Induction chemotherapy)
-
Guangzhou, Guangdong, China
- +3 more
Jul 30, 2023
Swallowing-induced Pain Trial in Guangzhou (doxepin solution, Placebo)
Not yet recruiting
- Swallowing-induced Pain
- doxepin solution
- Placebo
-
Guangzhou, Guangdong, ChinaSouthern medical university
Aug 24, 2023
Locally Advanced Nasopharyngeal Carcinoma Trial in Guangzhou (2 cycles induction chemo, 3 cycles induction chemo)
Recruiting
- Locally Advanced Nasopharyngeal Carcinoma
- 2 cycles induction chemotherapy
- 3 cycles induction chemotherapy
-
Guangzhou, Other (Non U.s.), ChinaFirst Affiliated Hospital, Sun Yat-Sen University
May 6, 2023
Nasopharyngeal Carcinoma Trial in Beijing (Donafenib)
Recruiting
- Nasopharyngeal Carcinoma
-
Beijing, Beijing, ChinaCancer Hospital of Medical College
Nov 28, 2022